Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 5/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399660 | 0.74 | IDO1 (0.41) | NOS1AXLIDO1CHEK1TDO2 | |
| SCHEMBL30414670 | 0.74 | IDO1 (0.41) | NOS1AXLIDO1CHEK1TDO2 | |
| SCHEMBL19153649 | 0.74 | IDO1 (0.40) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL25183087 | 0.70 | METAP2 (0.33) | NOS1AXLMETAP2 | |
| SCHEMBL23122212 | 0.69 | CYP1A2 (0.38) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL18238082 | 0.69 | METAP2 (0.37) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL1155424 | 0.68 | NOS1 (0.42) | NOS1AXLIDO1METAP2CDK2 | |
| SCHEMBL15378479 | 0.67 | NOS1 (0.36) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL1155016 | 0.65 | NOS1 (0.35) | NOS1IDO1CHEK1FGFR1FGFR2 | |
| SCHEMBL12321248 | 0.63 | NOS1 (0.56) | NOS1AXLIDO1TDO2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | NOS1 1257/4885AXL 2342/4885IDO1 1123/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | NOS1 1257/4885AXL 2342/4885IDO1 1123/4885 |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | IGF1R, IGFBP3, INSR | NOS1 2230/4885AXL 1837/4885IDO1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.